T1	p 81 128	children and adolescents with autistic disorder
T2	p 282 330	children and adolescents with autistic disorders
T3	p 406 511	patients ( 5-17 years of age , who completed the previous fixed-dose , 6 week , double-blind [ DB ] phase
T4	p 805 869	Fifty-six ( 71 % ) out of 79 enrolled patients completed the OLE
T5	i 66 77	risperidone
T6	i 220 231	risperidone
T7	i 539 550	risperidone
T8	i 724 735	risperidone
T9	i 1584 1595	risperidone
T10	i 1820 1831	risperidone
T11	i 2000 2011	risperidone
T12	o 739 745	safety
T13	o 748 756	efficacy
T14	o 953 969	adverse events (
T15	o 1065 1073	appetite
T16	o 1103 1122	weight and vomiting
T17	o 1146 1204	sedation , pyrexia , and upper respiratory tract infection
T18	o 1228 1243	nasopharyngitis
T19	o 1266 1288	somnolence and fatigue
T20	o 1327 1330	AEs
T21	o 1378 1392	in mean weight
T22	o 1409 1424	body mass index
T23	o 1483 1489	weight
T24	o 1517 1564	prolactin-related AE ( irregular menstruation )
T25	o 1646 1674	in sleep visual analog scale
T26	o 1730 1751	efficacy scale scores
T27	o 2119 2153	irritability and related behaviors